I think that point is completely missed by the world. The 100 mg dose is great. They really should have written the release different and said the 100 mg dose was proven effective and the 50 was not so the forge on with the 100 mg. Can't believe the drop as this is not a failure of the drug. I just am taking advantage of it.
I won't be surprised if this was done deliberately. The insiders know what they have in their cards, so the market can drop the pps 30% and it won't rattle them a bit, because of their confidence in their product. The retail trader/investor who is just trying to catch a ride in the momentum of a rising stock without the knowledge of the science are the ones who will sell with a drop like this. Especially to the ones using margin. The insiders /CEO knew what he was doing exactly. To the ones who knows the science, hold tight, and if it drops below $11.50....buy some more if you have the resources.
This is the second failure of a VMAT2 trial and brings into question whether O'Brien et al can run a succesful trial. Keep in mind that the on site AIMS evaluators they are now blaming were selected and trained by Neurocrine. When Abbott first partnered with Neurocrine they couldn't wait to pry Elagolix away from them, because they saw Neurcrine's drug development plan as fatally flawed. JMO.